ArticleFrontiers in cell and developmental biology2026
Cationic nanoparticles with disrupting neutrophil extracellular traps inhibit the progression of head and neck squamous cell carcinoma.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Roles of neutrophil extracellular traps in cancer immunotherapy resistance and therapeutic targeting.Biomarker research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Immune checkpoint inhibitors (ICIs) have demonstrated promising therapeutic potential in head and neck squamous cell carcinoma (HNSCC). However, their clinical efficacy remains limited due to low response rates, largely attributed to the highly immunosuppressive tumor microenvironment (TME). Neutrophil extracellular traps (NETs) have recently been implicated in tumor progression and immune regulation. Therefore, this study aims to investigate the role of NETs in the TME and metastasis of HNSCC, and then to utilize cationic nanoparticles (cNP) to efficiently disrupt NETs in order to improve the immunosuppressive TME and inhibit metastasis, thereby suppressing the progression of HNSCC. Methods: Histological and bioinformatics analyses were performed to evaluate NET-related signatures in HNSCC tissues and their association with immune cell infiltration. Results: Histological analysis revealed that the expression level of NETs in HNSCC tissue was significantly higher than that in adjacent normal tissue. Bioinformatics analysis revealed that high expression of myeloperoxidase (MPO) gene is closely related to immunosuppressive cell infiltration. Further analysis revealed that arm-level gain of the MPO gene was significantly correlated with a decrease in the infiltration levels of various immune cells. Discussion: This study reveals the key role of NETs in immune escape and metastasis of HNSCC and confirms that cNP disrupting NETs can synergistically enhance the efficacy of anti-PD-1 therapy, providing a new combination therapy strategy for HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.